Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Investigation of Pokemon-regulated proteins in hepatocellular carcinoma using mass spectrometry-based multiplex quantitative proteomics.

Bi X, Jin Y, Gao X, Liu F, Gao D, Jiang Y, Liu H.

Eur J Mass Spectrom (Chichester). 2013;19(2):111-21.

PMID:
24261083
2.

Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells.

Hu H, Ding X, Yang Y, Zhang H, Li H, Tong S, An X, Zhong Q, Liu X, Ma L, Liu Q, Liu B, Lu Z, Zhang D, Hu P, Ren H.

Am J Physiol Gastrointest Liver Physiol. 2014 Sep 15;307(6):G611-22. doi: 10.1152/ajpgi.00160.2014. Epub 2014 Jul 3.

3.

Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.

Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP.

J Proteome Res. 2005 Nov-Dec;4(6):2062-9.

PMID:
16335951
4.

Quantitative proteomics reveal up-regulated protein expression of the SET complex associated with hepatocellular carcinoma.

Li C, Ruan HQ, Liu YS, Xu MJ, Dai J, Sheng QH, Tan YX, Yao ZZ, Wang HY, Wu JR, Zeng R.

J Proteome Res. 2012 Feb 3;11(2):871-85. doi: 10.1021/pr2006999. Epub 2011 Dec 19.

PMID:
22082227
5.

The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study.

Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, Yang Y, Ren H.

J Proteomics. 2014 Jun 25;106:99-112. doi: 10.1016/j.jprot.2014.04.021. Epub 2014 Apr 24.

PMID:
24769235
6.

A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines.

Xiang Y, Liu Y, Yang Y, Hu H, Hu P, Ren H, Zhang D.

Oncol Rep. 2015 Sep;34(3):1249-60. doi: 10.3892/or.2015.4106. Epub 2015 Jul 3.

PMID:
26151126
7.

Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers.

Li C, Tan YX, Zhou H, Ding SJ, Li SJ, Ma DJ, Man XB, Hong Y, Zhang L, Li L, Xia QC, Wu JR, Wang HY, Zeng R.

Proteomics. 2005 Mar;5(4):1125-39.

PMID:
15759316
8.

Depletion of Pokemon gene inhibits hepatocellular carcinoma cell growth through inhibition of H-ras.

Zhang QL, Tian DA, Xu XJ.

Onkologie. 2011;34(10):526-31. doi: 10.1159/000332141. Epub 2011 Sep 23.

PMID:
21985851
9.

Pokemon promotes the invasiveness of hepatocellular carcinoma by enhancing MEF2D transcription.

Kong J, Liu X, Li X, Wu J, Wu N, Chen J, Fang F.

Hepatol Int. 2016 May;10(3):493-500. doi: 10.1007/s12072-015-9697-y. Epub 2016 Jan 21.

PMID:
26797719
10.

Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.

Sun W, Xing B, Sun Y, Du X, Lu M, Hao C, Lu Z, Mi W, Wu S, Wei H, Gao X, Zhu Y, Jiang Y, Qian X, He F.

Mol Cell Proteomics. 2007 Oct;6(10):1798-808. Epub 2007 Jul 12.

11.

Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.

Wang LN, Tong SW, Hu HD, Ye F, Li SL, Ren H, Zhang DZ, Xiang R, Yang YX.

J Cell Biochem. 2012 Dec;113(12):3762-72. doi: 10.1002/jcb.24250.

PMID:
22807371
12.

Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.

Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ.

Hepatobiliary Pancreat Dis Int. 2010 Jun;9(3):296-305.

13.

Pokemon siRNA Delivery Mediated by RGD-Modified HBV Core Protein Suppressed the Growth of Hepatocellular Carcinoma.

Kong J, Liu X, Jia J, Wu J, Wu N, Chen J, Fang F.

Hum Gene Ther Methods. 2015 Oct;26(5):175-80. doi: 10.1089/hgtb.2015.093. Epub 2015 Sep 10.

PMID:
26356810
14.

Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.

Megger DA, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F, Hoffmann AC, Stephan C, Kuhlmann K, Eisenacher M, Schlaak JF, Baba HA, Meyer HE, Sitek B.

Mol Cell Proteomics. 2013 Jul;12(7):2006-20. doi: 10.1074/mcp.M113.028027. Epub 2013 Mar 5.

15.

Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.

Sun S, Lee NP, Poon RT, Fan ST, He QY, Lau GK, Luk JM.

Liver Int. 2007 Oct;27(8):1021-38. Review.

PMID:
17845530
17.
18.

A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.

Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S, Torbenson M, Pandey A, Thuluvath PJ.

J Proteome Res. 2008 Oct;7(10):4289-98. doi: 10.1021/pr800197z. Epub 2008 Aug 21.

19.

Differential proteomic analysis of hepatocellular carcinoma.

Corona G, De Lorenzo E, Elia C, Simula MP, Avellini C, Baccarani U, Lupo F, Tiribelli C, Colombatti A, Toffoli G.

Int J Oncol. 2010 Jan;36(1):93-9.

PMID:
19956837
20.

Isobaric labeling and tandem mass spectrometry: a novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation.

Romero R, Kusanovic JP, Gotsch F, Erez O, Vaisbuch E, Mazaki-Tovi S, Moser A, Tam S, Leszyk J, Master SR, Juhasz P, Pacora P, Ogge G, Gomez R, Yoon BH, Yeo L, Hassan SS, Rogers WT.

J Matern Fetal Neonatal Med. 2010 Apr;23(4):261-80. doi: 10.3109/14767050903067386.

PMID:
19670042

Supplemental Content

Support Center